[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-ovary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-ovary-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100647972","phase-1-a-phase-i-study-to-evaluate-the-safetypharmacokineticspharmacodynamicsand-efficacy-of-tj037130-in-adult-participants-with-advanced-solid-tumors-100647972",false,"NCT07715747","A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors","Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Males or females aged 18 years or older;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n* Voluntarily enroll in the study and be able to comply with scheduled visits, treatment schedules, laboratory tests and other study procedures;\n* Participants with histologically and\u002For cytologically confirmed recurrent or metastatic advanced malignant tumors for whom no standard therapy with clinical benefit is available, or who are ineligible for existing standard treatment regimens. Claudin 6 (CLDN6) positive expression confirmed by immunohistochemistry (IHC) ;\n* Agree to provide archived tumor tissue or fresh biopsy tumor samples (not mandatory during the dose escalation phase);\n* Have at least one evaluable tumor lesion per RECIST Version 1.1 (dose escalation phase); have at least one measurable tumor lesion per RECIST Version 1.1 (dose expansion phase);\n* All acute adverse events resulting from prior anticancer therapies have resolved to Grade ≤ 1 or baseline per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (excluding toxicities judged by the Investigator to pose no safety risk, such as alopecia, peripheral neurotoxicity, hypothyroidism stabilized with hormone replacement therapy, etc.);\n* Be deemed an appropriate candidate for this clinical trial by the Investigator with an expected survival of ≥ 12 weeks;\n* Demonstrate adequate organ function within 7 days prior to the first dose of study drug;\n* Male and female participants of childbearing potential must agree to use two forms of effective contraception throughout the study period and for 6 months after the last dose of TJ037130. In addition, female participants of childbearing potential must have a negative serum or urine pregnancy test.\n\nExclusion Criteria:\n\n* Prior exposure to CLDN6-targeted therapy;\n* Prior exposure to 4-1BB agonists;\n* Received PD-1\u002FPD-L1 therapy or other immune checkpoint inhibitors\u002Fagonists within 28 days prior to the first dose of study drug;\n* History of a second malignancy within the past 3 years, except cutaneous squamous cell carcinoma, cutaneous basal cell carcinoma, or carcinoma in situ of the cervix;","ALL","18 Years",{"count":19,"type":20},128,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical trial is to evaluate the safety and tolerability of TJ037130 in participants with advanced or metastatic solid tumors, and to determine the Potential Optimal Biological Dose (POBD) of TJ037130 for subsequent investigations.",[26,27,28,29],"Solid Tumor","Metastatic Ovary Cancer","Metastatic Gastric Cancer","Metastatic Endometrial Carcinoma","NOT_YET_RECRUITING","2026-07-16",{"date":33,"type":34},"2026-07-20","ACTUAL",{"date":36,"type":20},"2026-08-21",{"date":38,"type":20},"2028-06-30",{"name":40,"class":41},"TJ Biopharma Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":42},"100500493","phase-3-measuring-oncological-value-of-exercise-and-statin-100500493","NCT05796973","Measuring Oncological Value of Exercise and Statin","Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin","MOVES","Inclusion Criteria:\n\n* The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started\n* Prostate cancer: First course of docetaxel treatment or second-generation antiandrogen treatment for metastatic prostate cancer.\n* Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status.\n* Kidney cancer: Kidney cancer, for which 1st-line cancer drug treatment is started as tki monotherapy and\u002For IO monotherapy or as a combination therapy.\n* Ovarian cancer: stage III or IV cancer for which chemotherapy treatment is started.\n* The patient agrees to the study and signs a written informed consent.\n* Adult (18 years=\\>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study.\n* In women, the use of a reliable contraceptive during the intervention\n\nExclusion Criteria:\n\n* High risk of bone fractures\n* Inability to physical exertion and\u002For unsuitability for cancer drug treatment\n* Poor co-operation ability for psychological reasons\n* Active use of cholesterol-lowering drugs\n* Severe liver or kidney failure\n* Troublesome side effects that occurred in the past during cholesterol medication\n* Continuous use of medicinal substances that interact with atorvastatin during the study period\n* A special group of subjects according to the EU Clinical Trials Regulation 536\u002F2014 (e.g. pregnant or lactating women)\n\nExclusion criteria in patients who are already using statin medication before the study:\n\n* High risk of bone fractures\n* Inability to physical exertion and\u002For unsuitability for cancer drug treatment\n* Poor co-operation ability for psychological reasons\n* Severe liver or kidney failure\n* A special group of subjects according to the EU Clinical Trials Regulation 536\u002F2014 (e.g. pregnant or lactating women)","99 Years",{"count":53,"type":20},240,[55],"PHASE3","The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.",[58,59,60,61,62,63,64,65,66,67,68,27],"Prostate Cancer","Breast Cancer","Kidney Cancer","Ovarian Cancer","Metastatic Breast Cancer","Metastatic Kidney Cancer","Metastatic Renal Cell Carcinoma","Metastatic Renal Cancer","Metastatic Prostate Cancer","Metastatic Prostate Adenocarcinoma","Metastatic Ovarian Cancer","RECRUITING","2025-06-23",{"date":72,"type":34},"2025-06-27",{"date":74,"type":34},"2023-03-31",{"date":76,"type":20},"2027-12-31",{"name":78,"class":79},"Tampere University Hospital","OTHER"]